Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab and Cobimetinib in PD-1/PD-L1 Resistant or Refractory NSCLC
NCT03600701Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Nov 2018
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of atezolizumab, cobimetinib in non-small cell lung cancer (NSCLC), sponsored by National Cancer Institute. Started Nov 2018; status: active, not recruiting.
02
Drugs
atezolizumabcobimetinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03600701.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03600701.